Professor Beka Solomon, PhD, is Full Professor in the Department of Molecular Microbiology and Biotechnology at Tel Aviv University. She earned her PhD in 1976 from the Weizmann Institute of Science, Israel. She joined Tel Aviv University in 1979 following post-doctoral studies and training periods at Harvard Medical School and Brigham and Women’s Hospital, Boston, and at various other institutions in England and the United States. In 2002, she became Full Professor and headed the Neuroimmunology Laboratory in the same department.
In 2007, Dr. Solomon was included in Scientific American’s List of 50 of the World’s Leading Innovators. In 2010, she was visiting professor in the Laboratory of Neuroimmunology and Innate Immunity at Harvard University.
Dr. Solomon is a member of the editorial board of Drugs of Today, Recent Patents on CNS Drug Discovery, Neurodegenerative Disease, and the Journal of Alzheimer’s Disease. She is a recipient of the prestigious Zenith Award of the Alzheimer’s Association, USA, being the first recipient in Israel, and of the Dana Foundation Award for Neuroimmunology. Dr. Solomon was the incumbent of the Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University from 2003 to 2012, when she became Professor Emeritus at Tel Aviv University. A pioneer in vaccine development against neurodegenerative diseases, she has the distinction of being the first investigator to recognize the potential for anti–beta amyloid antibodies as a therapy for Alzheimer’s disease.
